Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.60 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.59 |
| ▸ | PDE8A | O60658 | 3/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | LITAF | Q99732 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775916 | 0.93 | PDE7A (0.60) | PDE7APDE7BPDE8AESR1SIGMAR1 | |
| SCHEMBL10322055 | 0.91 | PDE7A (0.60) | PDE7APDE7BPDE8ASIGMAR1CYP3A4 | |
| SCHEMBL100064 | 0.90 | PDE7A (0.61) | PDE7APDE7BPDE8ASIGMAR1CYP3A4 | |
| SCHEMBL173169 | 0.90 | PDE7A (0.56) | PDE7APDE7BPDE8AESR1SIGMAR1 | |
| SCHEMBL99845 | 0.90 | PDE7A (0.62) | PDE7APDE7BPDE8AESR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL141195 | 0.90 | PDE7A (0.60) | PDE7APDE7BPDE8ASIGMAR1CYP3A4 | |
| SCHEMBL100025 | 0.89 | PDE7A (0.56) | PDE7APDE7BPDE8ATNFLITAF | |
| SCHEMBL100671 | 0.88 | PDE7A (0.77) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL99714 | 0.88 | PDE7A (0.76) | PDE7APDE7BPDE8AESR1SIGMAR1 | |
| SCHEMBL7883412 | 0.87 | PDE7A (0.66) | PDE7APDE7BPDE8ASIGMAR1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | claimed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | claimed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | claimed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | claimed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | claimed |
| EP-2416777-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-02-15 | — | — | EP | claimed |
| WO-2010116090-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | claimed |
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| WO-2010116090-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010109148-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109148-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| EP-2205593-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009077680-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077680-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | PDE7A 1769/4885PDE7B 937/4885PDE8A 2886/4885 |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.